Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T16769
(Former ID: TTDI02333)
|
|||||
Target Name |
X-linked inhibitor of apoptosis protein (XIAP)
|
|||||
Synonyms |
hILP; hIAP3; hIAP-3; Xlinked IAP; X-linked IAP; RING-type E3 ubiquitin transferase XIAP; Inhibitor of apoptosis protein 3; ILP; IAPlike protein; IAP3; IAP-like protein; IAP-3; E3 ubiquitinprotein ligase XIAP; E3 ubiquitin-protein ligase XIAP; Baculoviral IAP repeatcontaining protein 4; Baculoviral IAP repeat-containing protein 4; BIRC4; API3
|
|||||
Gene Name |
XIAP
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 1 Target-related Diseases | + | ||||
1 | Metastatic lymph node neoplasm [ICD-11: 2D60] | |||||
Function |
Acts as a direct caspase inhibitor. Directly bind to the active site pocket of CASP3 and CASP7 and obstructs substrate entry. Inactivates CASP9 by keeping it in a monomeric, inactive state. Acts as an E3 ubiquitin-protein ligase regulating NF-kappa-B signaling and the target proteins for its E3 ubiquitin-protein ligase activity include: RIPK1, CASP3, CASP7, CASP8, CASP9, MAP3K2/MEKK2, DIABLO/SMAC, AIFM1, CCS and BIRC5/survivin. Ubiquitinion of CCS leads to enhancement of its chaperone activity toward its physiologic target, SOD1, rather than proteasomal degradation. Ubiquitinion of MAP3K2/MEKK2 and AIFM1 does not lead to proteasomal degradation. Plays a role in copper homeostasis by ubiquitinationg COMMD1 and promoting its proteasomal degradation. Can also function as E3 ubiquitin-protein ligase of the NEDD8 conjugation pathway, targeting effector caspases for neddylation and inactivation. Regulates the BMP signaling pathway and the SMAD and MAP3K7/TAK1 dependent pathways leading to NF-kappa-B and JNK activation. Acts as an important regulator of innate immune signaling via regulation of Nodlike receptors (NLRs). Protects cells from spontaneous formation of the ripoptosome, a large multi-protein complex that has the capability to kill cancer cells in a caspase-dependent and caspase-independent manner. Suppresses ripoptosome formation by ubiquitinating RIPK1 and CASP8. Acts as a positive regulator of Wnt signaling and ubiquitinates TLE1, TLE2, TLE3, TLE4 and AES. Ubiquitination of TLE3 results in inhibition of its interaction with TCF7L2/TCF4 thereby allowing efficient recruitment and binding of the transcriptional coactivator beta-catenin to TCF7L2/TCF4 that is required to initiate a Wnt-specific transcriptional program. Multi-functional protein which regulates not only caspases and apoptosis, but also modulates inflammatory signaling and immunity, copper homeostasis, mitogenic kinase signaling, cell proliferation, as well as cell invasion and metastasis.
Click to Show/Hide
|
|||||
BioChemical Class |
Acyltransferase
|
|||||
UniProt ID | ||||||
EC Number |
EC 2.3.2.27
|
|||||
Sequence |
MTFNSFEGSKTCVPADINKEEEFVEEFNRLKTFANFPSGSPVSASTLARAGFLYTGEGDT
VRCFSCHAAVDRWQYGDSAVGRHRKVSPNCRFINGFYLENSATQSTNSGIQNGQYKVENY LGSRDHFALDRPSETHADYLLRTGQVVDISDTIYPRNPAMYSEEARLKSFQNWPDYAHLT PRELASAGLYYTGIGDQVQCFCCGGKLKNWEPCDRAWSEHRRHFPNCFFVLGRNLNIRSE SDAVSSDRNFPNSTNLPRNPSMADYEARIFTFGTWIYSVNKEQLARAGFYALGEGDKVKC FHCGGGLTDWKPSEDPWEQHAKWYPGCKYLLEQKGQEYINNIHLTHSLEECLVRTTEKTP SLTRRIDDTIFQNPMVQEAIRMGFSFKDIKKIMEEKIQISGSNYKSLEVLVADLVNAQKD SMQDESSQTSLQKEISTEEQLRRLQEEKLCKICMDRNIAIVFVPCGHLVTCKQCAEAVDK CPMCYTVITFKQKIFMS Click to Show/Hide
|
|||||
3D Structure | Click to Show 3D Structure of This Target | AlphaFold | ||||
HIT2.0 ID | T14LSK |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 6 Clinical Trial Drugs | + | ||||
1 | AT-406 | Drug Info | Phase 3 | Squamous head and neck cell carcinom | [2] | |
2 | Birinapant | Drug Info | Phase 2 | Lymphoma | [3], [4] | |
3 | Phenoxodiol | Drug Info | Phase 1/2 | Ovarian cancer | [5] | |
4 | APG-1387 | Drug Info | Phase 1 | Haematological malignancy | [6] | |
5 | GDC-0152 | Drug Info | Phase 1 | Obesity | [7] | |
6 | HGS-1029 | Drug Info | Phase 1 | Haematological malignancy | [8] | |
Mode of Action | [+] 3 Modes of Action | + | ||||
Inhibitor | [+] 1 Inhibitor drugs | + | ||||
1 | AT-406 | Drug Info | [9], [10] | |||
Modulator | [+] 3 Modulator drugs | + | ||||
1 | Birinapant | Drug Info | [1], [11] | |||
2 | Phenoxodiol | Drug Info | [12] | |||
3 | GDC-0152 | Drug Info | [7] | |||
Antagonist | [+] 36 Antagonist drugs | + | ||||
1 | APG-1387 | Drug Info | [13] | |||
2 | HGS-1029 | Drug Info | [14] | |||
3 | PMID25980951-Compound-1 | Drug Info | [15] | |||
4 | PMID25980951-Compound-10 | Drug Info | [15] | |||
5 | PMID25980951-Compound-11 | Drug Info | [15] | |||
6 | PMID25980951-Compound-12 | Drug Info | [15] | |||
7 | PMID25980951-Compound-13 | Drug Info | [15] | |||
8 | PMID25980951-Compound-14 | Drug Info | [15] | |||
9 | PMID25980951-Compound-15 | Drug Info | [15] | |||
10 | PMID25980951-Compound-19 | Drug Info | [15] | |||
11 | PMID25980951-Compound-20 | Drug Info | [15] | |||
12 | PMID25980951-Compound-21 | Drug Info | [15] | |||
13 | PMID25980951-Compound-22 | Drug Info | [15] | |||
14 | PMID25980951-Compound-26 | Drug Info | [15] | |||
15 | PMID25980951-Compound-27 | Drug Info | [15] | |||
16 | PMID25980951-Compound-28 | Drug Info | [15] | |||
17 | PMID25980951-Compound-29 | Drug Info | [15] | |||
18 | PMID25980951-Compound-3 | Drug Info | [15] | |||
19 | PMID25980951-Compound-30 | Drug Info | [15] | |||
20 | PMID25980951-Compound-31 | Drug Info | [15] | |||
21 | PMID25980951-Compound-32 | Drug Info | [15] | |||
22 | PMID25980951-Compound-33 | Drug Info | [15] | |||
23 | PMID25980951-Compound-36 | Drug Info | [15] | |||
24 | PMID25980951-Compound-37 | Drug Info | [15] | |||
25 | PMID25980951-Compound-38 | Drug Info | [15] | |||
26 | PMID25980951-Compound-39 | Drug Info | [15] | |||
27 | PMID25980951-Compound-4 | Drug Info | [15] | |||
28 | PMID25980951-Compound-40 | Drug Info | [15] | |||
29 | PMID25980951-Compound-41 | Drug Info | [15] | |||
30 | PMID25980951-Compound-42 | Drug Info | [15] | |||
31 | PMID25980951-Compound-43 | Drug Info | [15] | |||
32 | PMID25980951-Compound-44 | Drug Info | [15] | |||
33 | PMID25980951-Compound-45 | Drug Info | [15] | |||
34 | PMID25980951-Compound-5 | Drug Info | [15] | |||
35 | PMID25980951-Compound-6 | Drug Info | [15] | |||
36 | PMID25980951-Compound-7 | Drug Info | [15] |
Chemical Structure based Activity Landscape of Target | Top |
---|---|
Drug Property Profile of Target | Top | |
---|---|---|
(1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
||
(3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
||
(5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
||
"RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five |
Co-Targets | Top | |||||
---|---|---|---|---|---|---|
Co-Targets |
Target Poor or Non Binders | Top | |||||
---|---|---|---|---|---|---|
Target Poor or Non Binders |
Target Regulators | Top | |||||
---|---|---|---|---|---|---|
Target-regulating microRNAs | ||||||
Target-interacting Proteins |
Target Affiliated Biological Pathways | Top | |||||
---|---|---|---|---|---|---|
KEGG Pathway | [+] 8 KEGG Pathways | + | ||||
1 | NF-kappa B signaling pathway | |||||
2 | Ubiquitin mediated proteolysis | |||||
3 | Apoptosis | |||||
4 | Focal adhesion | |||||
5 | Toxoplasmosis | |||||
6 | HTLV-I infection | |||||
7 | Pathways in cancer | |||||
8 | Small cell lung cancer | |||||
Panther Pathway | [+] 1 Panther Pathways | + | ||||
1 | Apoptosis signaling pathway | |||||
PID Pathway | [+] 4 PID Pathways | + | ||||
1 | p75(NTR)-mediated signaling | |||||
2 | BMP receptor signaling | |||||
3 | Caspase Cascade in Apoptosis | |||||
4 | TGF-beta receptor signaling | |||||
Reactome | [+] 7 Reactome Pathways | + | ||||
1 | SMAC binds to IAPs | |||||
2 | SMAC-mediated dissociation of IAP:caspase complexes | |||||
3 | Deactivation of the beta-catenin transactivating complex | |||||
4 | RIPK1-mediated regulated necrosis | |||||
5 | Regulation of TNFR1 signaling | |||||
6 | TNFR1-induced NFkappaB signaling pathway | |||||
7 | Regulation of necroptotic cell death | |||||
WikiPathways | [+] 6 WikiPathways | + | ||||
1 | Copper homeostasis | |||||
2 | Focal Adhesion | |||||
3 | Apoptosis | |||||
4 | Intrinsic Pathway for Apoptosis | |||||
5 | Apoptosis Modulation and Signaling | |||||
6 | NOD pathway |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | cIAPs and XIAP regulate myelopoiesis through cytokine production in an RIPK1- and RIPK3-dependent manner. Blood. 2014 Apr 17;123(16):2562-72. | |||||
REF 2 | ClinicalTrials.gov (NCT04459715) A Study of Debio 1143 (Xevinapant) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy. U.S. National Institutes of Health. | |||||
REF 3 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7432). | |||||
REF 4 | ClinicalTrials.gov (NCT02147873) Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL. U.S. National Institutes of Health. | |||||
REF 5 | ClinicalTrials.gov (NCT00382811) OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer. U.S. National Institutes of Health. | |||||
REF 6 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 7 | Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). J Med Chem. 2012 May 10;55(9):4101-13. | |||||
REF 8 | ClinicalTrials.gov (NCT00708006) A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health. | |||||
REF 9 | Debio 1143, an antagonist of multiple inhibitor-of-apoptosis proteins, activates apoptosis and enhances radiosensitization of non-small cell lung c... Am J Cancer Res. 2014 Nov 19;4(6):943-51. | |||||
REF 10 | Debio 1143, an antagonist of multiple inhibitor-of-apoptosis proteins, activates apoptosis and enhances radiosensitization of non-small cell lung cancer cells in vitro. Am J Cancer Res. 2014; 4(6): 943-951. | |||||
REF 11 | Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF- B activation, and is active in patient-derived xenograft models. Mol Cancer Ther. 2014 Apr;13(4):867-79. | |||||
REF 12 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | |||||
REF 13 | XIAP Limits Autophagic Degradation of Sox2 and Is A Therapeutic Target in Nasopharyngeal Carcinoma Stem Cells.Theranostics. 2018 Feb 5;8(6):1494-1510. | |||||
REF 14 | Clinical pipeline report, company report or official report of Aegera Therapeutics Inc. | |||||
REF 15 | Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.